BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Costa A, Ai M, Nunn N, Culotta I, Hunter J, Boudjadja MB, Valencia-Torres L, Aviello G, Hodson DJ, Snider BM, Coskun T, Emmerson PJ, Luckman SM, D'Agostino G. Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation. Mol Metab 2021;55:101407. [PMID: 34844019 DOI: 10.1016/j.molmet.2021.101407] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Bass J, Tschöp MH, Beutler LR. Dual gut hormone receptor agonists for diabetes and obesity. J Clin Invest 2023;133. [PMID: 36719381 DOI: 10.1172/JCI167952] [Reference Citation Analysis]
2 Boer GA, Hay DL, Tups A. Obesity pharmacotherapy: incretin action in the central nervous system. Trends Pharmacol Sci 2023;44:50-63. [PMID: 36462999 DOI: 10.1016/j.tips.2022.11.001] [Reference Citation Analysis]
3 Chen J, Mei A, Wei Y, Li C, Qian H, Min X, Yang H, Dong L, Rao X, Zhong J. GLP-1 receptor agonist as a modulator of innate immunity. Front Immunol 2022;13:997578. [PMID: 36569936 DOI: 10.3389/fimmu.2022.997578] [Reference Citation Analysis]
4 Vergès B, Aboyans V, Angoulvant D, Boutouyrie P, Cariou B, Hyafil F, Mohammedi K, Amarenco P. Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms. Cardiovasc Diabetol 2022;21:242. [PMID: 36380358 DOI: 10.1186/s12933-022-01686-3] [Reference Citation Analysis]
5 Nauck MA, D‘alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovasc Diabetol 2022;21. [DOI: 10.1186/s12933-022-01604-7] [Reference Citation Analysis]
6 Smith C, Patterson-Cross R, Woodward O, Lewis J, Chiarugi D, Merkle F, Gribble F, Reimann F, Adriaenssens A. A comparative transcriptomic analysis of glucagon-like peptide-1 receptor- and glucose-dependent insulinotropic polypeptide-expressing cells in the hypothalamus. Appetite 2022;174:106022. [PMID: 35430298 DOI: 10.1016/j.appet.2022.106022] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
7 D'agostino G, Luckman SM. Brainstem peptides and peptidergic neurons in the regulation of appetite. Current Opinion in Endocrine and Metabolic Research 2022;24:100339. [DOI: 10.1016/j.coemr.2022.100339] [Reference Citation Analysis]